Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Oropharyngeal Candidiasis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Oropharyngeal Candidiasis - Pipeline Review, H1 2015', provides an overview of the Oropharyngeal Candidiasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Oropharyngeal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oropharyngeal Candidiasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Oropharyngeal Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Oropharyngeal Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Oropharyngeal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Oropharyngeal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Oropharyngeal Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Oropharyngeal Candidiasis Overview 6 Therapeutics Development 7 Pipeline Products for Oropharyngeal Candidiasis - Overview 7 Pipeline Products for Oropharyngeal Candidiasis - Comparative Analysis 8 Oropharyngeal Candidiasis - Therapeutics under Development by Companies 9 Oropharyngeal Candidiasis - Therapeutics under Investigation by Universities/Institutes 10 Oropharyngeal Candidiasis - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Oropharyngeal Candidiasis - Products under Development by Companies 14 Oropharyngeal Candidiasis - Products under Investigation by Universities/Institutes 15 Oropharyngeal Candidiasis - Companies Involved in Therapeutics Development 16 Eisai Co., Ltd. 16 Onxeo SA 17 Oropharyngeal Candidiasis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 E-1210 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 E-1211 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 miconazole - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Prof-002 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Oropharyngeal Candidiasis - Recent Pipeline Updates 30 Oropharyngeal Candidiasis - Discontinued Products 31 Oropharyngeal Candidiasis - Product Development Milestones 32 Featured News & Press Releases 32 Apr 01, 2014: BioAlliance Pharma provides an update on its partnerships for Loramyc/Oravig 32 Mar 12, 2013: Sosei Initiates Phase III Study For SO-1105 For Treatment Of Oropharyngeal Candidiasis 32 Jan 07, 2013: BioAlliance Pharma Announces Launch Of Oravig In US 33 Oct 18, 2012: BioAlliance Pharma Signs Agreement With Shafayab Gostar To Distribute Loramyc In Iran 33 Jul 02, 2012: Sosei Completes Phase I Study Of SO-1105 For Treatment Of Oropharyngeal Candidiasis 34 Mar 08, 2012: Sosei Initiates Phase I Study Of SO-1105 In Japan 34 Sep 07, 2011: BioAlliance Decides To Regain Full US Rights For Oravig 35 May 16, 2011: BioAlliance Pharma's Partner Therabel Launches Loramyc In Germany With Support Of Hikma 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables Number of Products under Development for Oropharyngeal Candidiasis, H1 2015 7 Number of Products under Development for Oropharyngeal Candidiasis - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Comparative Analysis by Unknown Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Oropharyngeal Candidiasis - Pipeline by Eisai Co., Ltd., H1 2015 16 Oropharyngeal Candidiasis - Pipeline by Onxeo SA, H1 2015 17 Assessment by Monotherapy Products, H1 2015 18 Number of Products by Stage and Target, H1 2015 19 Number of Products by Stage and Mechanism of Action, H1 2015 20 Number of Products by Stage and Route of Administration, H1 2015 22 Number of Products by Stage and Molecule Type, H1 2015 24 Oropharyngeal Candidiasis Therapeutics - Recent Pipeline Updates, H1 2015 30 Oropharyngeal Candidiasis - Discontinued Products, H1 2015 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.